Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era.

Abstract

BACKGROUND:

Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death.

METHODS:

This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics.

RESULTS:

The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL.

CONCLUSIONS:

Improved and/or additional treatment options are needed for these patient groups.

• Authors: Mark Soloway, Mack Roach 3rd
• Journal: Cancer (Cancer) Vol. 104 Issue 11 Pg. 2310-22 (Dec 01 2005) ISSN: 0008-543X [Print] United States
• PMID: 16222694 (Publication Type: Journal Article, Review)

Chemical References

• Prostate-Specific Antigen

Topics

• Brachytherapy
• Clinical Trials as Topic
• Disease Progression
• Humans
• Male
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (radiotherapy, therapy)